Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Congenital Urological Abnormalities Clear all

Conditions: Overactive Bladder
Interventions: onaBoNT-A, Oxybutynin ER; Drug
Lead sponsor: Christopher Patrick Smith; Other
Eligibility: 18 Years to 80 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Lower Urinary Tract Symptoms
Interventions: Lactobacillus rhamnosus GG; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Lower Urinary Tract Symptoms, Bladder Outlet Obstruction
Interventions: Mirabegron, Placebo; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 15
States / cities: Tuscon, Arizona • Atherton, California • Culver City, California + 12 more

Conditions: Congenital Urological Abnormalities
Interventions: mycophenolate mofetil; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 3 Years to 16 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 3
States / cities: New Brunswick, New Jersey • New Hyde Park, New York • New York, New York

Conditions: Fabry Disease
Interventions: PRX-102 (pegunigalsidase alfa), agalsidase beta; Biological
Lead sponsor: Protalix; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more

Conditions: Fabry Disease, Proteinuria
Interventions: enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 5
States / cities: Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more

Conditions: Genitourinary Abnormality, Breast Cancer Female, Vaginal Abnormality, Urinary Tract Infections, Dyspareunia, Dysuria
Interventions: Replens and coconut oil; Combination Product
Lead sponsor: Alta Bates Summit Medical Center; Other
Eligibility: Female only
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Spina Bifida, Kidney Transplant
Interventions: Behavioral Feedback and Economic Incentives: Arm 1, Behavioral Feedback and Economic Incentives: Arm 2; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 12 Years to 24 Years
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 6
States / cities: Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more

Conditions: Thalassemia Major
Interventions: Vitamin D3, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 6 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Sickle Cell Disease, Kidney Diseases, Chronic
Interventions: Biospecimen/DNA collection and analysis; Other
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • Winston-Salem, North Carolina • Memphis, Tennessee

Conditions: Fabry Disease, Proteinuria
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years to 95 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Neurogenic Detrusor Overactivity
Interventions: Darifenacin; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 2 Years to 15 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 9
States / cities: San Diego, California • Boston, Massachusetts • Detroit, Michigan + 6 more

Conditions: Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease, Hypercalcemia, Idiopathic, of Infancy, Hypercalciuric Hypercalcemia, Idiopathic Infantile Hypercalcemia - Mild Form, Hypercalciuria
Interventions: Rifampin; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Months to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fabry Disease
Interventions: This is a non-interventional study; Other
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Eagan, Minnesota

Conditions: Sickle Cell Anemia
Interventions: Ambrisentan, Placebo; Drug
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Sickle Cell Disease, Sickle Cell Nephropathy
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 60 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Kidney Calculi
Interventions: Potassium Citrate, Acetazolamide, Diet low in oxalate and purines; Drug · Behavioral
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 5 Years to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Urinary Incontinence, Cystic Fibrosis
Interventions: Reusable Underwear, Disposable urethral support, Pelvic floor physical therapy; Device · Behavioral
Lead sponsor: Megan Bradley; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Bladder Exstrophy, Urinary Incontinence
Interventions: MDC; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 2 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fibrosis, Focal Glomerulosclerosis, Kidney Failure, Nephrotic Syndrome, Proteinuria
Interventions: Pirfenidone; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Urinary Incontinence
Interventions: Perineal-applied electrical stimulation; Device
Lead sponsor: Elidah, Inc.; Industry
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Monroe, Connecticut

Conditions: Lower Urinary Tract Symptoms
Interventions: Lactobacillus; Drug
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 6 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Anemia, Sickle Cell, Sickle Cell Disease, Kidney Disease, Hypertension, Proteinuria
Interventions: Losartan; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 5 Years to 25 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Fabry Disease
Interventions: pegunigalsidase alfa; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 7
States / cities: Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more

Search by objective public record fields.

OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER

Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB

A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)

Pilot Study of Mycophenolate Mofetil in Congenital Uropathies

Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function

The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

Urological and Renal Disease Engaging Adolescents in Adherence Collaborative Trial

The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study

The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia

Antiproteinuric Agents and Fabry Disease

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

Understanding Fabry Disease Therapy Choices Through the Eyes of the Patients

The Role of Endothelin-1 in Sickle Cell Disease

Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease

Effects of Potassium Citrate in Urine of Children With Elevated Calcium in Urine and Kidney Stones

Cystic Fibrosis and Urinary Incontinence

Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence

Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)

Clinical Study of External Electrical Stimulation for Male Incontinence

Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB

Preventing Sickle Cell Kidney Disease

Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients